SERUM MIR-181А AND MIR-25 LEVELS IN PATIENTS WITH BREAST CANCEROR A BENIGN BREAST DISEASE

Abstract

Circulating miR-181а and miR-25, which reflect regulation of the expression of carcinogenesis-related genes, were assayed in patients with invasive carcinoma of no specific type (ICNT) or benign diseases of the breast (BDBs) and in people without pathologies of the mammary gland (controls). MiR-181а expression level proved to be higher compared to control in patients with fibroadenoma and adenosis with low but not high risk of malignant transformation as well as in patients with luminal HER2-negative type B (Lum B HER2–), HER2-positive type (HER2+) and triple-negative breast cancer (TNBC) than in the controls and luminal-type (Lum A) breast cancer. MiR-25 expression level prevailed in patients with Lum B HER2- compared to control, Lum A and TNBC; in patients with TNBC compared to Lum A. Thus, MiR-181а and miR-25 expression levels may be risk indicators of malignant transformation in some patients with BDBs, whereas in patients with ICNT, these levels reflect pathological processes of different directions within the tumor.